KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

NCT06384976 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Primary Progressive
Multiple Sclerosis, Secondary Progressive
Multiple Sclerosis
MS

Interventions

BIOLOGICAL: KYV-101
DRUG: Standard lymphodepletion regimen
DRUG: Anti-CD20 mAB

Sponsor

Kyverna Therapeutics